Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
RESEARCH TOOLSreports
Bolt Biotherapeutics (BOLT) Stock Price & Analysis
192 Followers
BOLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $1.56
Previous Close$0.72
Volume114.47K
Average Volume (3M)228.03K
Market Cap
$27.49M
Enterprise Value-$44.29M
Total Cash (Recent Filing)$91.35M
Total Debt (Recent Filing)$19.57M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 07, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding38,127,740
10 Day Avg. Volume186,265
30 Day Avg. Volume228,030
Standard Deviation0.22
R-Squared0.04
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)13.69
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.91
Enterprise Value/Gross Profit-5.62
Enterprise Value/Ebitda0.95
Forecast
1Y Price Target
$1.25Price Target Upside73.37% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bolt Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThere is considerable upside potential if one of the two ongoing programs demonstrates meaningful clinical activity.
Financial StabilityApprox. $112.8MN in cash and equivalents at the end of 1Q24, with management anticipating cash runway into 2H26.
Research FocusThe company is focusing on the continued development of BDC-3042, which targets a first-in-class tumor-associated macrophage (TAM)-polarizing mechanism.
Bears Say
Clinical Program RisksBoth ongoing clinical programs, BDC-3042 and the next-generation ISAC candidate, are considered high-risk due to their novelty and early stage of development.
Efficacy ConcernsThe initial dose-expansion cohorts of BDC-1001 failed to meet Bolt’s pre-specified 30% overall response rate efficacy threshold.
Strategic And Management ChangesThe company has discontinued their lead program, BDC-1001, and is undergoing strategic and management changes.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $0.72 and its highest was $1.56 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Currently, no data Available
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 31 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on May 14, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.51 by $0.23.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics does not currently pay dividends.
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -$0.48.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 38,127,740 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.51. Following the earnings report the stock price went down -37.121%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Among the largest hedge funds holding Bolt Biotherapeutics’s share is Hawkeye Capital Management, LLC. It holds Bolt Biotherapeutics’s shares valued at 581K.
---
Bolt Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.25 (73.37% Upside)
$1.25 (73.37% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.61%
12-Months-Change
Fundamentals
Return on Equity
-48.14%
Trailing 12-Months
Asset Growth
-30.70%
Trailing 12-Months
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
---
BOLT Stock 12 Month Forecast
Average Price Target
$1.25
▲(73.37% Upside)
Technical Analysis
---